

# CANCER GENOMICS & PROTEOMICS

Print ISSN: 1109-6535  
Online ISSN: 1790-6245

VOLUME 4, No 5  
2007



## Editorial Board

- A. Seth** Editor-in-Chief  
Laboratory of Molecular Pathology, Sunnybrook Research Institute, Sunnybrook Health Sciences Centre and University of Toronto, Toronto, Ontario, Canada
- J.G. Delinassios** Managing Editor and Executive Publisher,  
International Institute of Anticancer Research, Athens, Greece
- L.A. Aaltonen** Department of Medical Genetics, University of Helsinki, Finland  
**S. Aaronson** Derarld H. Ruttenberg Cancer Center, Mount Sinai School of Medicine, New York, NY, USA  
**R. Abagyan** The Scripps Research Institute, La Jolla, CA, USA  
**J.D. Aitchison** Institute for Systems Biology, Seattle, WA, USA  
**W. Ansorge** IAET, Borex, Switzerland  
**S. Antonarakis** Division of Medical Genetics, University of Geneva Medical School, Switzerland  
**F.G. Barr** Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA  
**A.M. Burger** Department of Pharmacology and Experimental Therapeutics, Greenebaum Cancer Center, University of Maryland School of Medicine, Baltimore, MD, USA
- A.M. Chinnaiyan** Department of Pathology, University of Michigan Medical School, Ann Arbor, MI, USA  
**B.F.C. Clark** Department of Molecular Biology, University of Aarhus, Denmark  
**R. Clarke** Vincent T. Lombardi Cancer Center, Georgetown University School of Medicine, Washington, DC, USA  
**I. Dunham** The Wellcome Trust Sanger Centre, Wellcome Trust Genome Campus, Cambridge, UK  
**N.A. Ellis** Department of Medicine University of Chicago, IL, USA  
**J.A. Fernandes-Pol** Metalloproteomics, LLC, Chesterfield, MO, USA  
**C.V. Forst** McClintock Resource, Bioscience Division, Los Alamos National Laboratory, NM, USA  
**M. Fountoulakis** F. Hoffman - La Roche Pharmaceutical Research, Basel, Switzerland  
**W.L. Gerald** Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA  
**J.W. Gray** Cancer Genetics Program, Comprehensive Cancer Center, University of California San Francisco, CA, USA  
**B.B. Haab** Van Andel Research Institute, Grand Rapids, MI, USA  
**C.-H. Heldin** Ludwig Institute for Cancer Research, Uppsala, Sweden  
**J.D. Hoheisel** Deutsches Krebsforschungszentrum, Genome Research and Bioinformatics, Heidelberg, Germany  
**R.P. Huang** Department of Gynecology and Obstetrics, Emory University School of Medicine, Atlanta, GA, USA  
**T.H.M. Huang** Comprehensive Cancer Center, Human Cancer Genetics Program, Ohio State University, Columbus, OH, USA
- Y. Ito** Institute of Molecular and Cell Biology, Oncology Research Institute, Yon Loo Lin School of Medicine, National University of Singapore, Singapore
- V.C. Jordan** Fox Chase Cancer Center, Philadelphia, PA, USA  
**A. Kallioniemi** Laboratory of Cancer Genetics, Institute of Medical Technology, Tampere University Hospital, Finland  
**O.P. Kallioniemi** Medical Biotechnology Group, VTT Technical Research Centre of Finland, Turku, Finland  
**M. Kanehisa** Bioinformatics Center, Institute for Chemical Research, Kyoto University, Japan  
**S.E. Kern** Department of Oncology, The Johns Hopkins School of Medicine, Baltimore, MD, USA  
**K. Khalili** College of Science and Technology, Center for Neurovirology and Cancer Biology, Temple University, Philadelphia, PA, USA
- S.D. Kottaridis** Department of Virology, Hellenic Anticancer Institute, Athens, Greece  
**B. Leyland-Jones** Winship Cancer Center, Emory University School of Medicine, Atlanta, GA, USA  
**P. Lichter** Deutsches Krebsforschungszentrum, Heidelberg, Germany  
**A. Lindblom** Karolinska Hospital, Department of Molecular Medicine and Surgery, Stockholm, Sweden  
**G. Lubec** Department of Pediatrics, University of Vienna, Austria  
**J. Lyons-Weiler** Department of Pathology, Center for Oncology Informatics, University of Pittsburgh, PA, USA  
**P.J. McCormick** Center for Comp. Functional Genomics, VA Medical Center University at Albany, SUNY, Rensselaer, NY, USA
- J.D. Minna** Hamon Center for Therapeutic Oncology, University of Texas, Southwestern Medical Center at Dallas, TX, USA
- F. Mitelman** Department of Clinical Genetics, University Hospital, Lund, Sweden  
**P. Nelson** Fred Hutchinson Cancer Research Center, Seattle, WA, USA  
**C. Nicot** Department of Microbiology, Immunology and Molecular Genetics, University of Kansas Medical Center, Kansas City, KS, USA
- L. O'Driscoll** National Institute for Cellular Biotechnology, Dublin City University, Dublin, Ireland

**R. Ohlsson** Department of Development and Genetics, Evolution Biology Center, Uppsala University, Sweden  
**I. Pastan** Laboratory of Molecular Biology, NCI, NIH, Bethesda, MD, USA  
**C.D. Platsoucas** College of Sciences, Old Dominion University, Norfolk, VA, USA  
**J. Quackenbush** Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA  
**G. Rechavi** Pediatric Hemato-Oncology Department, Sheba Medical Center, Tel-Hashomer, Israel  
**R.H. Reeves** Department of Physiology, Johns Hopkins University, School of Medicine, Baltimore, MD, USA  
**K.L. Reichelt** Institute of Pediatric Research, The National Hospital, University of Oslo, Norway  
**T. Ried** Center for Cancer Research, Genetics Branch, NCI, NIH, Bethesda, MD, USA  
**G. Rimbach** Institute for Human Nutrition and Food Science, Christian-Albrechts-University, Kiel, Germany  
**K.D. Rodland** Biological Sciences Division, Pacific Northwest National Laboratory, Richland, WA, USA  
**C. Sansom** The School of Crystallography, Birbeck College, University of London, UK  
**Y. Sakaki** Human Genome Research Group, RIKEN Genomic Sciences Center, Yokohama, Japan  
**N.A. Saunders** Centre for Immunology and Cancer Research, Princess Alexandra Hospital, University of Queensland, Australia  
**S.W. Scherer** The Hospital for Sick Children, Department of Genetics, University of Toronto, ON, Canada  
**G.V. Sherbet** University of Newcastle, Merz Court, Department of Electrical and Electronic Engineering, Newcastle-upon-Tyne, UK  
  
**Y. Shimonishi** Nagahama Institute of Bioscience and Technology, Shiga, Japan  
**K.K. Singh** Department of Cancer Genetics, Roswell Park Cancer Institute, Buffalo, NY, USA  
**S. Smith** City of Hope Cancer Center, Department of Cell and Tumor Biology, Duarte, CA, USA  
**D. Sudar** Life Sciences Division, Lawrence Berkeley Laboratory, Berkeley, CA, USA  
**A.-C. Syvänen** Department of Medical Sciences, Uppsala University Hospital, Sweden  
**K. Tanaka** Department of Orthopaedic Surgery, Kyushu University, Fukuoka, Japan  
**J.M. Trent** Tgen, Phoenix, AZ, USA  
**G. Tsangaris** Foundation of Biomedical Research of the Academy of Athens, Central Unit of Genomics- Proteomics, Athens, Greece  
  
**L.-C. Tsui** The Hospital for Sick Children, University of Toronto, ON, Canada  
**A. Ullrich** Department of Molecular Biology, Max-Planck Institute of Biochemistry, Martinsried, Germany  
**G.F. Vande Woude** Laboratory of Molecular Oncology, Van Andel Institute, Grand Rapids, MI, USA  
**D.K. Watson** Department of Biochemistry and Molecular Biology, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, USA  
  
**I.B. Weinstein** Herbert Irving Comprehensive Cancer Center, Columbia University College of Physicians and Surgeons, New York, NY, USA  
  
**K. Williams** Keck Laboratory, Department of Molecular Biophysics and Biochemistry, New Haven, CT, USA  
**A.T. Yeung** Fox Chase Cancer Center, Philadelphia, PA, USA  
**H. Zhang** Department of Epidemiology and Public Health, Yale University School of Medicine, New Haven, CT, USA

Articles in **CANCER GENOMICS & PROTEOMICS** are regularly indexed in the following bibliographic services: PUBMED - MEDLINE, CAS (Chemical Abstracts Service); BIOLOGICAL ABSTRACTS; EMBASE and BIOBASE, Compendex, GEOBASE, EMBiology, FLUIDEX, Scopus (Elsevier Bibliographic Databases); BIOSIS PREVIEWS; LEEDS MEDICAL INFORMATION; CSA ILLUMINA (Cambridge Scientific Abstracts, including: Oncogenes & Growth Factors, Genetics, Medical & Pharmaceutical Biotechnology, Bioengineering); All-Russian Institute of Scientific and Technical Information – VINITI Abstracts Journal; PubsHub, Sociedad Iberoamericana de Información Científica (SIIC) Data Bases.

#### **Editorial Office:**

International Institute of Anticancer Research  
 1st km Kapandritiou-Kalamou Road,  
 P.O. Box 22, Kapandriti, Attiki, 19014, Greece.  
 Tel: 0030 22950 52945, Fax: 0030 22950 53389  
 e-mail: journals@iiar-anticancer.org. Website: www.iiar-anticancer.org

Manuscripts, correspondence, requests for sample copies and orders should be addressed to: Dr. John G. Delinassios, Managing Editor, Editorial Office, Cancer Genomics & Proteomics, 1st km Kapandritiou-Kalamou Road, P.O. Box 22, Kapandriti, Attiki, 19014, Greece. Tel: 0030 22950 52945, Fax: 0030 22950 53389, e-mail (Editorial Office): journals@iiar-anticancer.org, e-mail (Managing Editor): editor@iiar-anticancer.org

Manuscripts from North America may be sent to the Editor-in-Chief, Prof. A. Seth, CGP, Laboratory of Molecular Pathology, Sunnybrook and Women's College Health Sciences Center, 2075 Bayview Avenue, Room E-423, Toronto, ON, Canada M4N 3M5. Fax: 416 978 5956, e-mail: genomics.proteomics@utoronto.ca

# CANCER GENOMICS & PROTEOMICS

Volume 4, Number 5, September-October 2007

## Contents

* Collagen – A Necessary Accomplice in the Metastatic Process. P.S. NERENBERG, R. SALSAS-ESCAT, C.M. STULTZ ( <i>Cambridge, MA, U.S.A.</i> ) .....	319
Differential Expression of Ribosomal Proteins in a Human Metastasis Model Identified by Coupling 2-D Liquid Chromatography and Mass Spectrometry. P. KREUNIN, C. YOO, V. URQUIDI, D.M. LUBMAN, S. GOODISON ( <i>Michigan; Ann Arbor, MI; Jacksonville, FL, U.S.A.</i> ).....	329
17HSD 2 may be Higher in African-American Breast Cancer and is Associated with Estrogen Receptor-negative Tumors. R. YAEGER, P.C. NOLAN, T. SU, A. AVILA-BRONT, X. WANG, Y.-K. K. CHEUNG, H. LIU, V.S. RANGARAJAN, H. HIBSHOOSH, C.A. POWELL, A.K. JOE ( <i>New York, NY, U.S.A.</i> ) .....	341
* Molecular Profiling for the Identification of New Biomarkers in Smokers and Cancer Patients. K. ALBERMANN, S. LANG, R. ZEIDLER ( <i>Essen; Munich, Germany</i> ).....	349
Genome-wide Expression Profiling Reveals New Insights into Pathogenesis and Progression of Testicular Germ Cell Tumors. K. BIERMANN, L.S.C. HEUKAMP, K. STEGER, H. ZHOU, F.E. FRANKE, V. SONNACK, R. BREHM, J. BERG, P.J. BASTIAN, S.C. MÜLLER, L. WANG-ECKERT, R. BUETTNER ( <i>Bonn; Giessen; Cologne, Germany</i> ) .....	359
Activity of the Glutathione Peroxidase-2. Differences in the Selenium-dependent Expression between Colon and Small Intestine. J. BARTEL, T. BARTZ, C. WOLF, E. CHARKIEWICZ, M. KÜHBACHER, T. POHL, A. KYRIAKOPOULOS ( <i>Berlin; Teltow, Germany</i> ).....	369
Errata .....	373
* Reviews (pages 319, 349)	

# Instructions to Authors

**General Policy.** CANCER GENOMICS & PROTEOMICS (CGP) welcomes the submission of high quality original articles and reviews on all aspects of the application of genomic and proteomic technologies to experimental and clinical cancer research. The journal's scientific spectrum includes: (a) molecular causes of carcinogenesis, cancer progression and metastasis; (b) structural and functional aspects of genes in the cancer cell; (c) advances in genomic and proteomic technologies applicable to cancer research; (d) anticancer drug design and drug development.

CGP will also accept abstracts and proceedings of scientific meetings for publication, following consideration and approval by the Editorial Board.

A main aim of CGP is to ensure for the prompt publication of original works of high quality, generally within 1-2 months from final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works that are not under consideration for publication by another journal, and that they will not be published again in the same form. All material submitted to CGP will be subject to review by two members of the Editorial Board and by one suitable outside referee. All manuscripts submitted to CGP are treated in confidence, with access restricted to the Editor-in-Chief, the Managing Editor, the journal's secretary, the reviewers and the printers. The Editors reserve the right to improve manuscripts in terms of grammar and style.

**Copyright.** On publication of a manuscript in CGP, which is a copyrighted publication, the legal ownership of all published parts of the paper passes from the Author(s) to the Journal. Material published in the journal may not be reproduced or published elsewhere without the written consent of the Managing Editor.

**Format.** Two types of papers may be submitted: (i) full papers containing completed original work, and (ii) review articles concerning fields of recognizable progress. Papers should contain all the essential data in order to make the presentation clear. Papers should be written in clear, concise English. Spelling should follow that of the "Oxford English Dictionary".

**Manuscripts.** Submitted manuscripts should not exceed fourteen (14) pages (approximately 250 words per double-spaced page), including abstract, text, tables, figures, and references (corresponding to 4 printed pages). Papers exceeding four (4) printed pages will be subject to excess page charges. All manuscripts should be divided into the following sections: (a) First page including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) Abstract not exceeding 2000 words, organized according to the following headings: Background - Materials and Methods or Patients and Methods - Results - Conclusion; (c) Introduction; (d) Materials and Methods or Patients and Methods; (e) Results; (f) Discussion; (g) Acknowledgements and (h) References. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author's preference. Review articles should not exceed 35 pages (approximately 250 words per double-spaced page) including all tables, figures and references.

**Figures.** All figures (whether photographs or graphs) should be clear, high contrast, glossy prints of the size they are to appear in the journal: 8.00 cm (3.15 in.) wide for a single column; 17.00 cm (6.70 in.) for a double column; maximum height: 20.00 cm (7.87 in.). Graphs must be submitted as photographs made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated on the reverse side. Original karyotypes and photographs should be provided wherever possible, rather than photographic copies. A charge will be made for a colour plate. Figures should be numbered with Arabic numerals and include a short title, and legend if appropriate.

**Tables.** Each table should be submitted on a separate page, double-spaced. Tables should be numbered with Roman numerals and should include a short title, and legend if appropriate.

**References.** Authors must assume responsibility for the accuracy of the references used. Citations for the reference section of submitted works should follow the standard form of "Index Medicus" and must be numbered consecutively in the order that they appear in the text. Examples: 1 Sumner AT: The nature of chromosome bands and their significance for cancer research. *Anticancer Res* 1: 205-216, 1981. 2. McGuire WL and Chamness GC: Studies on the oestrogen receptor in breast cancer. *In: Receptors for Reproductive Hormones* (O' Malley BW and Chamness GC, eds.). New York, Plenum Publ Corp, pp.133-136, 1973. In the text, references should be denoted as: (1), (2-5), (6, 7) etc.

**Nomenclature and Abbreviations.** Nomenclature should follow that given in "Chemical Abstracts", "Index Medicus", "Merck Index", "IUPAC-IUB", "Bergey's Manual of Determinative Bacteriology", The CBE Manual for Authors, Editors and Publishers (6th edition, 1994), and MIAME Standard for Microarray Data. Human gene symbols may be obtained from the HUGO Gene Nomenclature Committee (HGNC) (<http://www.gene.ucl.ac.uk/>). Approved mouse nomenclature may be obtained from <http://www.informatics.jax.org/>. Standard abbreviations are preferable. If a new abbreviation is used, it must be defined on first usage.

**Ethical Policies and Standards.** CGP agrees with and follows the "Uniform Requirements for Manuscripts Submitted to Biomedical Journals" established by the International Committee of Medical Journal Editors in 1978 and updated in October 2001 ([www.icmje.org](http://www.icmje.org)). Microarray data analysis should comply with the "Minimum Information About Microarray Experiments (MIAME) standard". Specific guidelines are provided at the "Microarray Gene Expression Data Society" (MGED) website. Presentation of genome sequences should follow the guidelines of the NHGRI Policy on Release of Human Genomic Sequence Data. Research involving human beings must adhere to the principles of the Declaration of Helsinki and Title 45, U.S. Code of Federal Regulations, Part 46, Protection of Human Subjects, effective December 13, 2001. Research involving animals must adhere to the Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society. The use of animals in biomedical research should be under the careful supervision of a person adequately trained in this field and the animals must be treated humanely at all times. Research involving the use of human foetuses, foetal tissue, embryos and embryonic cells should adhere to the U.S. Public Law 103-41, effective December 13, 2001.

**Submission of Manuscripts.** An original and two copies of the manuscript (including all photographs and graphs) should be sent to: Dr. J.G. Delinassios, Managing Editor, Cancer Genomics and Proteomics, International Institute of Anticancer Research, 1st km Kapandritiou-Kalamou Rd., Kapandriti, P.O. Box 22, Attiki 19014, Greece. A CD-ROM, floppy disc, or ZIP-disc should also be submitted indicating the computer-processing program. Additionally, for speed of processing, manuscripts may be sent by e-mail to [www.cgp-journal.com](http://www.cgp-journal.com). Authors are invited to submit, along with their manuscripts, a short list of possible reviewers and any previous publications which could facilitate reviewing. Only the original copy of the submitted manuscript will be returned to the Authors upon rejection.

**Galley Proofs.** Unless otherwise indicated, galley proofs will be sent by e-mail to the first-named Author of the submission. Corrections of galley proofs should be limited to typographical errors.

**Reprints.** Twenty-five copies of each communication will be provided free of charge. Additional copies may be ordered after acceptance of the paper. Requests for additional reprints should be addressed to the Editorial Office.